Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • May 12
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding). Board Change • May 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 17
Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 21,636,603
Price\Range: AUD 0.047
Discount Per Security: AUD 0.00282
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,638,298
Price\Range: AUD 0.047
Discount Per Security: AUD 0.00282
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Mar 31
Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 31,914,893
Price\Range: AUD 0.047
Discount Per Security: AUD 0.00282
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Oct 16
Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,200,000
Price\Range: AUD 0.085
Transaction Features: Subsequent Direct Listing Tillkännagivande • Sep 29
Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025 Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025. Tillkännagivande • Aug 30
Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million. Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,222,222
Price\Range: AUD 0.063
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jun 26
Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million. Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,095,238
Price\Range: AUD 0.063
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Mar 05
Firebrick Pharma Limited announced that it expects to receive AUD 1.1 million in funding from Pharma Nutria N.a. (metro Manila Luzon), Inc. Firebrick Pharma Limited announce that it has secured an investment from Pharma Nutria N.A., Inc to issue 11,578,947 ordinary shares at a price of AUD 0.095 per share for gross proceeds of AUD 1,099,999.965 on March 4, 2025. The Shares are subject to a voluntary escrow of 12 months. The 11,578,947 Shares will represent 5.2% of all Firebrick shares outstanding and therefore PNAI will become a substantial shareholder in Firebrick. Tillkännagivande • Oct 29
Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024 Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024. Tillkännagivande • Oct 17
Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million. Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,885,454
Price\Range: AUD 0.055
Discount Per Security: AUD 0
Transaction Features: Subsequent Direct Listing Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023) Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023). Tillkännagivande • Sep 15
Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold Firebrick Pharma Limited announced that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray as a treatment for the common cold. The analysis has shown that the trial did not meet its primary endpoint, which was the impact of Nasodine on overall cold severity (GSS) in subjects with a confirmed viral infection (ITTi). Based on the reported results, the placebo (sterile water) performed better than Nasodine. In the QoL (`quality-of-life') measure (functional impairment caused by a cold), the results were also in favour of the placebo in the ITTi. Similar enigmatic results were seen in other population subsets. The results provided to the Company are shown in the table titled: Trial Headline Results Summary. These results are compared in summary form with the previous (2019) Phase 3 trial in the table titled: Phase 3 Trial Comparisons on Key Endpoints. The 2019 trial used the same protocol and treatment regimen as the current (2022-23) trialand both trials were robust Phase 3 trials. The 2019 trial took place in Australia, so a comparison of the results with the current trial for Australian sites only has been undertaken (not shown in summary tables). In the 2019 trial, the GSS benefit of Nasodine in the viral-infected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024). The reported results also appear to conflict with the Company's recently reported Phase 2 COVID-19 trial, where Nasodine treatment led to 100% clearance of the SARS-CoV-2 virus from the nasal passages. That result was significantly better than the placebo (p=0.028), which was the same water placebo as used in the 2022-23 Phase 3 trial. The Company is concerned that the results are so confounding, unexpected and at odds with previous data that there may be a systematic error or other issue in the data, and a detailed analysis is now underway to try to identify any causes of such an error. To that end, the Company is working with the Contract Research Organisation (CRO) responsible for trial governance and other service providers to thoroughly investigate the trial results. At this time, there is no evidence that the placebo and Nasodine treatments were switched during production, distribution or treatment. Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022) Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022). Tillkännagivande • Jul 22
Firebrick Update on Administrative Appeals Tribunal Process Firebrick Pharma Limited announced that the scheduled conciliation meeting with the TGA (Therapeutic Goods Administration), which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023. The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine Nasal Spray ("Nasodine"). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached. This announcement was authorized for release by Dr. Peter Molloy, Executive Chairman, Firebrick Pharma Limited. Tillkännagivande • May 16
Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023 Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023, at 11:00 E. Australia Standard Time. Agenda: To consider the ratification of tranche 1 placement shares; to consider the issue of tranche 2 placement shares to related party Stephen Goodall; and to consider the issue of tranche 2 placement shares to related party Peter Molloy. Board Change • Mar 30
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Richard Treagus was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
